Rationale for effective interventions to mitigate oral mucositis in patients being treated with TROP-2-directed antibody-drug conjugates with a topoisomerase inhibitor payload
Abstract
Clinically significant oral mucositis (OM) is a frequently reported toxicity of TROP-2 directed ADCs containing a topoisomerase inhibitor payload, such as datapotamab deruxtecan (Dato-DXd). It seems likely that the mechanism underlying this important toxicity is consistent with the established biological cascade associated with other cytotoxic regimens and a consequence of the expression of TROP-2 on normal oral mucosa. Since it is probable that the biological processes underlying TROP-2 ADC induced OM are distinct from the inflammatory pathogenesis of stomatitis caused by mTOR inhibitors (mIAS), a rational interventional strategy which recognizes these different biological targets is critical for developing effective prevention and treatment.
Fields of Study & Subjects
HER2/EGFR in Cancer Research
Colorectal Cancer Treatments and Studies
Oral health in cancer treatment
Publication details
- Journal / source
- Oral Oncology Reports
- Publisher
- Elsevier BV
- Volume
- 18
- Pages
- 100784–100784
- Publication date
- 12 February 2026
- Language
- EN